Literature DB >> 1537396

Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat.

D Orosz1, J P Bennett.   

Abstract

L-DOPA is frequently used to relieve symptoms of Parkinson's disease (PD), but its use in patients with more advanced PD is complicated by on-off phenomena. We used simultaneous microdialysis of striatum and ipsilateral substantia nigra to characterize changes in extracellular fluid (ecf) levels of dopamine (DA) following systemic treatment with L-DOPA (25 mg/kg as methylester) in awake, normal rats and those with partial (less than 99%) or complete (greater than 99%) DA depleting unilateral lesions of the nigrostriatal pathway (nsp). In normal rats, nigral ecf DA rose 17-fold above baseline after L-DOPA, compared to a 2.6-fold increase in normal striata. Striatal ecf DA rose equally after L-DOPA in all three groups, whereas peak nigral ecf DA in completely lesioned rats was three times that in normal or partially lesioned animals. Peak nigral ecf DA in completely lesioned rats exceeded striatal ecf DA in all groups by almost 2-fold. Activity after L-DOPA was biphasic ("hyperkinetic/bradykinetic") in completely lesioned but not in normal or partially lesioned animals, and the reduced activity occurred 2.5-4 h after L-DOPA at a time when both nigral and striatal ecf DA levels were still elevated. L-DOPA-induced increases in activity were predictable by greater elevations in nigral compared to striatal ecf DA in animals with complete lesions of the nigrostriatal pathway. Post-DOPA reduced activity might result from desensitization of synaptic events mediated by DA receptors; this may underlie DOPA-related on-off phenomena in patients with advanced PD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537396     DOI: 10.1016/0014-4886(92)90203-3

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease.

Authors:  D S Kreiss; C W Mastropietro; S S Rawji; J R Walters
Journal:  J Neurosci       Date:  1997-09-01       Impact factor: 6.167

Review 2.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

3.  Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.

Authors:  Elaine Del-Bel; Fernando Eduardo Padovan-Neto; Raphael Escorsim Szawka; Célia Aparecida da-Silva; Rita Raisman-Vozari; Janete Anselmo-Franci; Angélica Caroline Romano-Dutra; Francisco Silveira Guimaraes
Journal:  Neurotox Res       Date:  2013-06-27       Impact factor: 3.911

4.  Tyrosine Hydroxylase Inhibition in Substantia Nigra Decreases Movement Frequency.

Authors:  Michael F Salvatore; Tamara R McInnis; Mark A Cantu; Deana M Apple; Brandon S Pruett
Journal:  Mol Neurobiol       Date:  2018-07-28       Impact factor: 5.590

5.  Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.

Authors:  S Sarre; N De Klippel; P Herregodts; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

6.  Modification of L-DOPA pharmacological activity by MAO inhibitors.

Authors:  J P M Finberg; O Sader-Mazbar
Journal:  J Neural Transm (Vienna)       Date:  2007-04-10       Impact factor: 3.575

7.  Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Parkinsons Dis       Date:  2011-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.